Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 17Lymphoma, Non-Hodgkin 13Lymphoma, B-Cell 10Lymphoma 10Lymphoma, Follicular 7Recurrence 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, Mantle-Cell 3Leukemia 3Burkitt Lymphoma 3Solid Tumors 2Neoplasms 2Melanoma 2Colorectal Neoplasms 2Bronchiolitis Obliterans Syndrome 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Cancers 1Prostatic Neoplasms 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Mycosis Fungoides 1Mesothelioma 1Mature B-cell Malignancies 1Mature B-Cell Malignancies 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Etoposide 5Carboplatin 3Cisplatin 2oblimersen 1obinutuzumab 1gossypol acetic acid 1camrelizumab 1apatinib 1NVP-BKM120 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Extensive Stage Small Cell Lung Cancer × obinutuzumab × Clear all
NCT07107490 2026-02-06

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Chugai Pharmaceutical

Phase 1 Recruiting
122 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡